NASDAQ:LVGO - Livongo Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $98.65
  • Forecasted Upside: -29.03 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$139.00
▲ +1.03 (0.75%)
1 month | 3 months | 12 months
Get New Livongo Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LVGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LVGO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$98.65
▼ -29.03% Downside Potential
This price target is based on 17 analysts offering 12 month price targets for Livongo Health in the last 3 months. The average price target is $98.65, with a high forecast of $170.00 and a low forecast of $41.00. The average price target represents a -29.03% upside from the last price of $139.00.
Buy
The current consensus among 17 contributing investment analysts is to buy stock in Livongo Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$88.00 ➝ $150.00Low
i
8/24/2020Stifel NicolausDowngradeBuy ➝ Hold$137.00High
i
Rating by David Grossman at Stifel Nicolaus
8/17/2020Canaccord GenuityBoost Price TargetBuy$110.00 ➝ $139.00High
i
8/11/2020CitigroupBoost Price TargetBuy$125.00 ➝ $170.00Medium
i
Rating by Daniel Grosslight at Citigroup Inc.
8/7/2020BenchmarkDowngradeBuy ➝ HoldHigh
i
8/6/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
i
7/14/2020Credit Suisse GroupInitiated CoverageOutperform$132.00High
i
7/14/2020CitigroupInitiated CoverageBuy$125.00Low
i
7/9/2020Canaccord GenuityBoost Price TargetOutperform ➝ Buy$69.00 ➝ $110.00High
i
7/8/2020Needham & Company LLCBoost Price TargetBuy$70.00 ➝ $120.00Low
i
7/8/2020Royal Bank of CanadaBoost Price TargetOutperform$53.00 ➝ $120.00Low
i
7/7/2020KeyCorpBoost Price Target$85.00 ➝ $105.00Medium
i
7/7/2020Morgan StanleyBoost Price TargetOverweight$62.00 ➝ $89.00High
i
7/6/2020StephensInitiated CoverageOverweight$95.00High
i
7/2/2020Goldman Sachs GroupDowngradeBuy ➝ Neutral$48.00 ➝ $70.00Low
i
6/25/2020CowenBoost Price TargetOutperform$69.00 ➝ $88.00Medium
i
6/22/2020KeyCorpBoost Price TargetOverweight$52.00 ➝ $85.00High
i
6/12/2020SVB LeerinkBoost Price TargetOutperform$55.00 ➝ $65.00Low
i
Rating by Stephanie Davis at SVB Leerink LLC
6/5/2020CowenInitiated CoverageOutperform$69.00Medium
i
6/3/2020Canaccord GenuityBoost Price TargetBuy$65.00 ➝ $69.00High
i
Rating by Richard Close at Canaccord Genuity
5/22/2020JPMorgan Chase & Co.Boost Price TargetOverweight$36.00 ➝ $63.00Low
i
5/21/2020Needham & Company LLCBoost Price TargetBuy$55.00 ➝ $70.00High
i
5/7/2020Morgan StanleyBoost Price TargetOverweight$36.00 ➝ $62.00High
i
5/7/2020Royal Bank of CanadaBoost Price TargetOutperform$45.00 ➝ $53.00High
i
5/7/2020Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $65.00High
i
Rating by Richard Close at Canaccord Genuity
5/7/2020KeyCorpBoost Price TargetOverweight$46.00 ➝ $52.00Low
i
5/7/2020SVB LeerinkBoost Price TargetOutperform$49.00 ➝ $55.00Medium
i
Rating by Stephanie Davis at SVB Leerink LLC
5/7/2020Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $55.00Medium
i
5/7/2020Goldman Sachs GroupBoost Price TargetSell ➝ Buy$42.00 ➝ $48.00Medium
i
5/7/2020Piper SandlerBoost Price TargetOverweight$42.00 ➝ $55.00Medium
i
4/23/2020GuggenheimInitiated CoverageBuy$46.00High
i
4/21/2020BenchmarkInitiated CoverageBuy$55.00Medium
i
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$45.00Medium
i
4/13/2020SVB LeerinkInitiated CoverageOutperform$49.00Medium
i
3/30/2020Needham & Company LLCReiterated RatingBuy$42.00High
i
3/27/2020Morgan StanleyLower Price TargetOverweight$38.00 ➝ $36.00Medium
i
3/19/2020Stifel NicolausInitiated CoverageBuy$30.00High
i
3/12/2020Canaccord GenuityReiterated RatingBuy$46.00Medium
i
Rating by Richard Close at Canaccord Genuity
12/16/2019Canaccord GenuityReiterated RatingBuy$46.00Low
i
Rating by Richard Close at Canaccord Genuity
11/7/2019Piper Jaffray CompaniesBoost Price TargetOverweight$40.00 ➝ $41.00Low
i
8/28/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$42.00High
i
8/19/2019SVB LeerinkInitiated CoverageOutperform$50.00High
i
Rating by D. Grosslight at SVB Leerink LLC
8/19/2019Morgan StanleyInitiated CoverageEqual Weight$42.00High
i
8/19/2019JPMorgan Chase & Co.Initiated CoverageOverweight$43.00Medium
i
8/19/2019Canaccord GenuityInitiated CoverageBuy$46.00Medium
i
8/19/2019Goldman Sachs GroupInitiated CoverageBuy$43.00Medium
i
8/19/2019KeyCorpInitiated CoverageOverweight$46.00Medium
i
8/19/2019Needham & Company LLCInitiated CoverageBuy$42.00Medium
i
8/19/2019Piper Jaffray CompaniesInitiated CoverageOverweight$40.00Medium
i
8/16/2019Chardan CapitalInitiated CoverageNeutral$40.00 ➝ $40.00High
i
(Data available from 10/23/2015 forward)
Livongo Health logo
Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $139.00
$136.50
$139.29

50 Day Range

MA: $135.41
$121.72
$148.08

52 Week Range

Now: $139.00
$18.76
$151.05

Volume

34,795 shs

Average Volume

3,041,141 shs

Market Capitalization

$14.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77